London, UK – Ipsos Healthcare, the global healthcare division of Ipsos, has announced the launch of its syndicated Hyperlipidemia Therapy Monitor – the latest addition to its Global Therapy Monitor Portfolio, which reveals drug shares, future prescribing intentions, attributes that drive doctors’ decision-making, and more.
The new monitor focuses specifically on hyperlipidemia patients with familial hypercholesterolemia or a resistance to statins. Treatment of this particular patient group is currently at a critical stage with the advancement of the highly-anticipated PCSK9 inhibitor class of drugs in phase III trials.
Explained Dr Sabina Heinz, Head of Ipsos Healthcare’s Cardiovascular & Diabetes Therapy Monitor Portfolio:
“The PCSK9 inhibitors are currently showing very strong results in Phase 3 trials, and have the potential to transform the treatment of hyperlipidemia patients with familial hypercholesterolemia or statin-resistance.
“Ipsos Healthcare’s new monitor puts the magnifying glass onto this specific patient group, enabling pharma and biotechs to gain an understanding of market potential and current unmet needs at a time when they need it most.”
The Hyperlipidemia Therapy Monitor will track hyperlipidemia treatment in the US, with the EU5 scheduled to follow in 2014. US data will be available at the beginning of Q1 2014. Given the crossover of this patient group with diabetes – another Therapy Monitor offered by Ipsos Healthcare – subscribers will be able to see a holistic picture of diabetes patients suffering from hyperlipidemia.
For more information on this news release please contact:
Dr Sabina Heinz
Head of Cardiovascular Therapy Monitors
+44 (0)203 0595298
Marketing Director, Syndicated Services
+44 7818 422117
About Ipsos Healthcare’s Global Therapy Monitors
Ipsos Healthcare’s Global Therapy Monitors comprise the industry’s largest portfolio of syndicated patient chart audit data. The suite of global studies tracks usage of treatments across 20+ disease areas, including Metabolics, Oncology, Virology, Autoimmune, Cardiovascular and more. Together, they encompass 4000 physicians reporting on 200,000 patients in 35 markets worldwide. Subscribers to the Global Therapy Monitors can track product usage and maintain a comprehensive understanding of their ever-evolving markets.
About Ipsos Healthcare
Ipsos Healthcare is a global specialised practice focusing on research in the pharmaceutical, bio-tech and medical device markets. It is also a leading provider of global syndicated patient chart studies in 35 markets. Operating in over 40 countries, the team of 500 healthcare market research experts, marketers and client-side brand-builders focuses on delivering outcome-oriented research for its clients. Drawing from a broad range of qualitative and quantitative techniques, Ipsos Healthcare offers custom and syndicated research programs to evaluate the motivations, experiences, interactions and influences of stakeholders forming the multi-customer markets that increasingly drive business success in the healthcare industry.
Ipsos is an independent market research company controlled and managed by research professionals. Founded in France in 1975, Ipsos has grown into a worldwide research group with a strong presence in all key markets. In October 2011 Ipsos completed the acquisition of Synovate. The combination forms the world’s third largest market research company. With offices in 85 countries, Ipsos delivers insightful expertise across six research specializations: advertising, customer loyalty, marketing, media, public affairs research, and survey management.
Ipsos researchers assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media and they measure public opinion around the globe.
Ipsos has been listed on the Paris Stock Exchange since 1999 and generated global revenues of €1,789 billion (2.300 billion USD) in 2012.
Visit www.ipsos.com to learn more about Ipsos’ offerings and capabilities.